What is Lifesci Capital’s Forecast for TENX Q1 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities researchers at Lifesci Capital issued their Q1 2026 earnings estimates for Tenax Therapeutics in a report released on Thursday, March 12th. Lifesci Capital analyst G. Maini expects that the specialty pharmaceutical company will earn ($0.38) per share for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Lifesci Capital also issued estimates for Tenax Therapeutics’ Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.46) EPS and FY2026 earnings at ($1.54) EPS.

A number of other brokerages have also recently commented on TENX. William Blair reaffirmed an “outperform” rating on shares of Tenax Therapeutics in a research note on Tuesday, March 10th. Guggenheim reissued a “buy” rating and set a $25.00 price objective (up from $14.00) on shares of Tenax Therapeutics in a research note on Wednesday, December 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tenax Therapeutics in a report on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $22.50.

Tenax Therapeutics Price Performance

Shares of TENX stock opened at $13.84 on Monday. The business has a 50-day moving average of $13.35 and a 200 day moving average of $10.01. Tenax Therapeutics has a 1-year low of $4.63 and a 1-year high of $18.38. The stock has a market capitalization of $86.36 million, a PE ratio of -10.41 and a beta of 1.41.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings data on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.88.

Institutional Trading of Tenax Therapeutics

Several large investors have recently modified their holdings of the business. Letko Brosseau & Associates Inc. purchased a new position in Tenax Therapeutics during the 4th quarter valued at about $130,000. Virtu Financial LLC purchased a new stake in Tenax Therapeutics in the 3rd quarter worth approximately $92,000. Corient Private Wealth LLC purchased a new stake in Tenax Therapeutics in the 4th quarter worth approximately $151,000. Quadrature Capital Ltd bought a new stake in shares of Tenax Therapeutics in the 4th quarter worth approximately $252,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Tenax Therapeutics in the 4th quarter worth approximately $273,000. 1.67% of the stock is owned by institutional investors.

About Tenax Therapeutics

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.